HEADER RECEPTOR 29-APR-08 2VSR TITLE HPPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH 9-(S)-HODE COMPND MOL_ID: 1; COMPND 2 MOLECULE: PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA; COMPND 3 CHAIN: A, B; COMPND 4 FRAGMENT: LIGAND BINDING DOMAIN, RESIDUES 202-475; COMPND 5 SYNONYM: PPAR GAMMA, NUCLEAR RECEPTOR SUBFAMILY 1 GROUP C COMPND 6 MEMBER 3; COMPND 7 ENGINEERED: YES; COMPND 8 OTHER_DETAILS: 9-(S)-HODE SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 6 EXPRESSION_SYSTEM_TAXID: 511693; SOURCE 7 EXPRESSION_SYSTEM_STRAIN: BL21; SOURCE 8 EXPRESSION_SYSTEM_VARIANT: ROSETTA; SOURCE 9 EXPRESSION_SYSTEM_PLASMID: PET30A MODIFIED KEYWDS TRANSCRIPTION REGULATION, ALTERNATIVE SPLICING, LIGAND KEYWDS 2 BINDING DOMAIN, NUCLEAR RECEPTOR, DIABETES MELLITUS, KEYWDS 3 ZINC-FINGER, DNA-BINDING, POLYMORPHISM, TRANSCRIPTION, KEYWDS 4 ZINC, OBESITY, NUCLEUS, RECEPTOR, ACTIVATOR, OXIDISED KEYWDS 5 FATTY ACID, TRANSCRIPTION FACTOR, METAL-BINDING, KEYWDS 6 PHOSPHOPROTEIN, DISEASE MUTATION EXPDTA X-RAY DIFFRACTION AUTHOR T.ITOH,L.FAIRALL,J.W.R.SCHWABE REVDAT 4 06-JUN-12 2VSR 1 SOURCE JRNL REMARK VERSN REVDAT 4 2 HETNAM FORMUL REVDAT 3 24-FEB-09 2VSR 1 VERSN REVDAT 2 28-OCT-08 2VSR 1 JRNL REVDAT 1 19-AUG-08 2VSR 0 JRNL AUTH T.ITOH,L.FAIRALL,K.AMIN,Y.INABA,A.SZANTO, JRNL AUTH 2 B.L.BALINT,L.NAGY,K.YAMAMOTO,J.W.R.SCHWABE JRNL TITL STRUCTURAL BASIS FOR THE ACTIVATION OF PPARG BY JRNL TITL 2 OXIDISED FATTY ACIDS JRNL REF NAT.STRUCT.MOL.BIOL. V. 15 924 2008 JRNL REFN ISSN 1545-9993 JRNL PMID 19172745 JRNL DOI 10.1038/NSMB.1474 REMARK 2 REMARK 2 RESOLUTION. 2.05 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : CNS 1.2 REMARK 3 AUTHORS : BRUNGER,ADAMS,CLORE,DELANO,GROS,GROSSE- REMARK 3 : KUNSTLEVE,JIANG,KUSZEWSKI,NILGES,PANNU, REMARK 3 : READ,RICE,SIMONSON,WARREN REMARK 3 REMARK 3 REFINEMENT TARGET : MLF REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.05 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 51.02 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.0 REMARK 3 DATA CUTOFF HIGH (ABS(F)) : 1954557.35 REMARK 3 DATA CUTOFF LOW (ABS(F)) : NULL REMARK 3 COMPLETENESS (WORKING+TEST) (%) : 94.4 REMARK 3 NUMBER OF REFLECTIONS : 39198 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING SET) : 0.226 REMARK 3 FREE R VALUE : 0.266 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 5.0 REMARK 3 FREE R VALUE TEST SET COUNT : 1975 REMARK 3 ESTIMATED ERROR OF FREE R VALUE : 0.006 REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : 6 REMARK 3 BIN RESOLUTION RANGE HIGH (A) : 2.05 REMARK 3 BIN RESOLUTION RANGE LOW (A) : 2.18 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : 79.5 REMARK 3 REFLECTIONS IN BIN (WORKING SET) : 5152 REMARK 3 BIN R VALUE (WORKING SET) : 0.278 REMARK 3 BIN FREE R VALUE : 0.307 REMARK 3 BIN FREE R VALUE TEST SET SIZE (%) : 5.3 REMARK 3 BIN FREE R VALUE TEST SET COUNT : 286 REMARK 3 ESTIMATED ERROR OF BIN FREE R VALUE : 0.018 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 4105 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 63 REMARK 3 SOLVENT ATOMS : 119 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : 21.7 REMARK 3 MEAN B VALUE (OVERALL, A**2) : 34.2 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : -0.64 REMARK 3 B22 (A**2) : 10.13 REMARK 3 B33 (A**2) : -9.49 REMARK 3 B12 (A**2) : 0.00 REMARK 3 B13 (A**2) : 2.31 REMARK 3 B23 (A**2) : 0.00 REMARK 3 REMARK 3 ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM LUZZATI PLOT (A) : 0.26 REMARK 3 ESD FROM SIGMAA (A) : 0.23 REMARK 3 LOW RESOLUTION CUTOFF (A) : 5.00 REMARK 3 REMARK 3 CROSS-VALIDATED ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM C-V LUZZATI PLOT (A) : 0.31 REMARK 3 ESD FROM C-V SIGMAA (A) : 0.27 REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES. REMARK 3 BOND LENGTHS (A) : 0.007 REMARK 3 BOND ANGLES (DEGREES) : 1.1 REMARK 3 DIHEDRAL ANGLES (DEGREES) : 18.7 REMARK 3 IMPROPER ANGLES (DEGREES) : 0.75 REMARK 3 REMARK 3 ISOTROPIC THERMAL MODEL : RESTRAINED REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. RMS SIGMA REMARK 3 MAIN-CHAIN BOND (A**2) : 1.38 ; 1.50 REMARK 3 MAIN-CHAIN ANGLE (A**2) : 2.18 ; 2.00 REMARK 3 SIDE-CHAIN BOND (A**2) : 2.20 ; 2.00 REMARK 3 SIDE-CHAIN ANGLE (A**2) : 3.28 ; 2.50 REMARK 3 REMARK 3 BULK SOLVENT MODELING. REMARK 3 METHOD USED : FLAT MODEL REMARK 3 KSOL : 0.4 REMARK 3 BSOL : 52.3926 REMARK 3 REMARK 3 NCS MODEL : NULL REMARK 3 REMARK 3 NCS RESTRAINTS. RMS SIGMA/WEIGHT REMARK 3 GROUP 1 POSITIONAL (A) : NULL ; NULL REMARK 3 GROUP 1 B-FACTOR (A**2) : NULL ; NULL REMARK 3 REMARK 3 PARAMETER FILE 1 : PROTEIN_REP.PARAM REMARK 3 PARAMETER FILE 2 : WATER_REP.PARAM REMARK 3 PARAMETER FILE 3 : 9H.PARAM REMARK 3 PARAMETER FILE 4 : NULL REMARK 3 TOPOLOGY FILE 1 : PROTEIN.TOP REMARK 3 TOPOLOGY FILE 2 : WATER.TOP REMARK 3 TOPOLOGY FILE 3 : 9H.TOP REMARK 3 TOPOLOGY FILE 4 : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: BULK SOLVENT MODEL USED REMARK 4 REMARK 4 2VSR COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBE ON 29-APR-08. REMARK 100 THE PDBE ID CODE IS EBI-36026. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 16-NOV-07 REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : 8 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : ESRF REMARK 200 BEAMLINE : ID14-3 REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 0.93 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : CCD REMARK 200 DETECTOR MANUFACTURER : ADSC REMARK 200 INTENSITY-INTEGRATION SOFTWARE : MOSFLM REMARK 200 DATA SCALING SOFTWARE : SCALA REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 39198 REMARK 200 RESOLUTION RANGE HIGH (A) : 2.05 REMARK 200 RESOLUTION RANGE LOW (A) : 51.02 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : 0.0 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 94.4 REMARK 200 DATA REDUNDANCY : 2.3 REMARK 200 R MERGE (I) : 0.05 REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : 13.50 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 2.05 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 2.16 REMARK 200 COMPLETENESS FOR SHELL (%) : 77.5 REMARK 200 DATA REDUNDANCY IN SHELL : 2.2 REMARK 200 R MERGE FOR SHELL (I) : 0.27 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : 2.90 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: PHASER REMARK 200 STARTING MODEL: PDB ENTRY 2I4P REMARK 200 REMARK 200 REMARK: NONE REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 55.5 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.8 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: NULL REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: C 1 2 1 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X,Y,-Z REMARK 290 3555 X+1/2,Y+1/2,Z REMARK 290 4555 -X+1/2,Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 2 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 -1.000000 0.00000 REMARK 290 SMTRY1 3 1.000000 0.000000 0.000000 46.59100 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 30.83700 REMARK 290 SMTRY3 3 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 4 -1.000000 0.000000 0.000000 46.59100 REMARK 290 SMTRY2 4 0.000000 1.000000 0.000000 30.83700 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1, 2 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: MONOMERIC REMARK 350 SOFTWARE USED: PQS REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 350 REMARK 350 BIOMOLECULE: 2 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: MONOMERIC REMARK 350 SOFTWARE USED: PQS REMARK 350 APPLY THE FOLLOWING TO CHAINS: B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 GLY A 202 REMARK 465 ALA A 203 REMARK 465 LEU A 204 REMARK 465 ASN A 205 REMARK 465 PRO A 206 REMARK 465 LYS A 263 REMARK 465 PHE A 264 REMARK 465 LYS A 265 REMARK 465 HIS A 266 REMARK 465 ILE A 267 REMARK 465 THR A 268 REMARK 465 PRO A 269 REMARK 465 LEU A 270 REMARK 465 GLN A 271 REMARK 465 GLU A 272 REMARK 465 GLN A 273 REMARK 465 SER A 274 REMARK 465 LEU A 476 REMARK 465 TYR A 477 REMARK 465 GLY B 202 REMARK 465 ALA B 203 REMARK 465 LEU B 204 REMARK 465 ASN B 205 REMARK 465 PRO B 206 REMARK 465 THR B 241 REMARK 465 THR B 242 REMARK 465 LEU B 270 REMARK 465 GLN B 271 REMARK 465 GLU B 272 REMARK 465 GLN B 273 REMARK 465 SER B 274 REMARK 465 GLU B 460 REMARK 465 THR B 461 REMARK 465 ASP B 462 REMARK 465 MET B 463 REMARK 465 SER B 464 REMARK 465 LEU B 465 REMARK 465 ASP B 475 REMARK 465 LEU B 476 REMARK 465 TYR B 477 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 LYS A 240 43.61 -74.79 REMARK 500 THR A 242 -29.44 169.91 REMARK 500 THR B 238 -63.81 -94.82 REMARK 500 ILE B 267 103.54 -59.47 REMARK 500 LYS B 457 16.15 -68.16 REMARK 500 LYS B 458 50.30 -147.35 REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE 9HO A1477 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE 9HO A1478 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC3 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE 9HO B1476 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 2FVJ RELATED DB: PDB REMARK 900 A NOVEL ANTI-ADIPOGENIC PARTIAL AGONIST OF REMARK 900 PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR-GAMMA ( REMARK 900 PPARG) RECRUITSPPARG-COACTIVATOR-1 ALPHA ( REMARK 900 PGC1A) BUT POTENTIATES INSULINSIGNALING IN REMARK 900 VITRO REMARK 900 RELATED ID: 2VV2 RELATED DB: PDB REMARK 900 HPPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX REMARK 900 WITH 5-HEPA REMARK 900 RELATED ID: 1FM9 RELATED DB: PDB REMARK 900 THE 2.1 ANGSTROM RESOLUTION CRYSTAL REMARK 900 STRUCTURE OF THEHETERODIMER OF THE HUMAN REMARK 900 RXRALPHA AND PPARGAMMA LIGANDBINDING DOMAINS REMARK 900 RESPECTIVELY BOUND WITH 9-CIS RETINOIC REMARK 900 ACIDAND GI262570 AND CO-ACTIVATOR PEPTIDES. REMARK 900 RELATED ID: 2VV0 RELATED DB: PDB REMARK 900 HPPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX REMARK 900 WITH DHA REMARK 900 RELATED ID: 2VV1 RELATED DB: PDB REMARK 900 HPPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX REMARK 900 WITH 4-HDHA REMARK 900 RELATED ID: 2PRG RELATED DB: PDB REMARK 900 LIGAND-BINDING DOMAIN OF THE HUMAN REMARK 900 PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA REMARK 900 RELATED ID: 1KNU RELATED DB: PDB REMARK 900 LIGAND BINDING DOMAIN OF THE HUMAN REMARK 900 PEROXISOME PROLIFERATORACTIVATED RECEPTOR GAMMA REMARK 900 IN COMPLEX WITH A SYNTHETICAGONIST REMARK 900 RELATED ID: 1RDT RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF A NEW REXINOID BOUND REMARK 900 TO THE RXRALPHALIGAND BINDING DOAMIN IN THE REMARK 900 RXRALPHA/PPARGAMMA HETERODIMER REMARK 900 RELATED ID: 3PRG RELATED DB: PDB REMARK 900 LIGAND BINDING DOMAIN OF HUMAN PEROXISOME REMARK 900 PROLIFERATOR ACTIVATED RECEPTOR REMARK 900 RELATED ID: 2VV4 RELATED DB: PDB REMARK 900 HPPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX REMARK 900 WITH 6-OXOOTE REMARK 900 RELATED ID: 1I7I RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE LIGAND BINDING REMARK 900 DOMAIN OF HUMANPPAR-GAMMA IN COMPLEX WITH REMARK 900 THE AGONIST AZ 242 REMARK 900 RELATED ID: 1K74 RELATED DB: PDB REMARK 900 THE 2.3 ANGSTROM RESOLUTION CRYSTAL REMARK 900 STRUCTURE OF THEHETERODIMER OF THE HUMAN REMARK 900 PPARGAMMA AND RXRALPHA LIGANDBINDING DOMAINS REMARK 900 RESPECTIVELY BOUND WITH GW409544 AND 9- REMARK 900 CISRETINOIC ACID AND CO-ACTIVATOR PEPTIDES. REMARK 900 RELATED ID: 1FM6 RELATED DB: PDB REMARK 900 THE 2.1 ANGSTROM RESOLUTION CRYSTAL REMARK 900 STRUCTURE OF THEHETERODIMER OF THE HUMAN REMARK 900 RXRALPHA AND PPARGAMMA LIGANDBINDING DOMAINS REMARK 900 RESPECTIVELY BOUND WITH 9-CIS RETINOIC REMARK 900 ACIDAND ROSIGLITAZONE AND CO-ACTIVATOR REMARK 900 PEPTIDES. REMARK 900 RELATED ID: 1ZGY RELATED DB: PDB REMARK 900 STRUCTURAL AND BIOCHEMICAL BASIS FOR SELECTIVE REMARK 900 REPRESSIONOF THE ORPHAN NUCLEAR RECEPTOR LRH REMARK 900 -1 BY SHP REMARK 900 RELATED ID: 1PRG RELATED DB: PDB REMARK 900 LIGAND BINDING DOMAIN OF THE HUMAN REMARK 900 PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA REMARK 900 RELATED ID: 2F4B RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE LIGAND BINDING REMARK 900 DOMAIN OF HUMANPPAR-GAMMA IN COMPLEX WITH REMARK 900 AN AGONIST REMARK 900 RELATED ID: 2VST RELATED DB: PDB REMARK 900 HPPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX REMARK 900 WITH 13-(S)-HODE REMARK 900 RELATED ID: 2G0H RELATED DB: PDB REMARK 900 STRUCTURE-BASED DRUG DESIGN OF A NOVEL REMARK 900 FAMILY OF PPARPARTIAL AGONISTS: VIRTUAL REMARK 900 SCREENING, X-RAY CRYSTALLOGRAPHYAND IN VITRO/ REMARK 900 IN VIVO BIOLOGICAL ACTIVITIES REMARK 900 RELATED ID: 1WM0 RELATED DB: PDB REMARK 900 PPARGAMMA IN COMPLEX WITH A 2-BABA REMARK 900 COMPOUND REMARK 900 RELATED ID: 4PRG RELATED DB: PDB REMARK 900 0072 PARTIAL AGONIST PPAR GAMMA COCRYSTAL REMARK 900 RELATED ID: 2VV3 RELATED DB: PDB REMARK 900 HPPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX REMARK 900 WITH 4-OXODHA REMARK 900 RELATED ID: 1NYX RELATED DB: PDB REMARK 900 LIGAND BINDING DOMAIN OF THE HUMAN REMARK 900 PEROXISOME PROLIFERATORACTIVATED RECEPTOR GAMMA REMARK 900 IN COMPLEX WITH AN AGONIST REMARK 900 RELATED ID: 2G0G RELATED DB: PDB REMARK 900 STRUCTURE-BASED DRUG DESIGN OF A NOVEL REMARK 900 FAMILY OF PPARPARTIAL AGONISTS: VIRTUAL REMARK 900 SCREENING, X-RAY CRYSTALLOGRAPHYAND IN VITRO/ REMARK 900 IN VIVO BIOLOGICAL ACTIVITIES REMARK 999 REMARK 999 SEQUENCE REMARK 999 RESIDUE NUMBERING CORRESPONDS TO ISOFORM 1 DBREF 2VSR A 202 203 PDB 2VSR 2VSR 202 203 DBREF 2VSR A 204 477 UNP P37231 PPARG_HUMAN 202 475 DBREF 2VSR B 202 203 PDB 2VSR 2VSR 202 203 DBREF 2VSR B 204 477 UNP P37231 PPARG_HUMAN 202 475 SEQRES 1 A 276 GLY ALA LEU ASN PRO GLU SER ALA ASP LEU ARG ALA LEU SEQRES 2 A 276 ALA LYS HIS LEU TYR ASP SER TYR ILE LYS SER PHE PRO SEQRES 3 A 276 LEU THR LYS ALA LYS ALA ARG ALA ILE LEU THR GLY LYS SEQRES 4 A 276 THR THR ASP LYS SER PRO PHE VAL ILE TYR ASP MET ASN SEQRES 5 A 276 SER LEU MET MET GLY GLU ASP LYS ILE LYS PHE LYS HIS SEQRES 6 A 276 ILE THR PRO LEU GLN GLU GLN SER LYS GLU VAL ALA ILE SEQRES 7 A 276 ARG ILE PHE GLN GLY CYS GLN PHE ARG SER VAL GLU ALA SEQRES 8 A 276 VAL GLN GLU ILE THR GLU TYR ALA LYS SER ILE PRO GLY SEQRES 9 A 276 PHE VAL ASN LEU ASP LEU ASN ASP GLN VAL THR LEU LEU SEQRES 10 A 276 LYS TYR GLY VAL HIS GLU ILE ILE TYR THR MET LEU ALA SEQRES 11 A 276 SER LEU MET ASN LYS ASP GLY VAL LEU ILE SER GLU GLY SEQRES 12 A 276 GLN GLY PHE MET THR ARG GLU PHE LEU LYS SER LEU ARG SEQRES 13 A 276 LYS PRO PHE GLY ASP PHE MET GLU PRO LYS PHE GLU PHE SEQRES 14 A 276 ALA VAL LYS PHE ASN ALA LEU GLU LEU ASP ASP SER ASP SEQRES 15 A 276 LEU ALA ILE PHE ILE ALA VAL ILE ILE LEU SER GLY ASP SEQRES 16 A 276 ARG PRO GLY LEU LEU ASN VAL LYS PRO ILE GLU ASP ILE SEQRES 17 A 276 GLN ASP ASN LEU LEU GLN ALA LEU GLU LEU GLN LEU LYS SEQRES 18 A 276 LEU ASN HIS PRO GLU SER SER GLN LEU PHE ALA LYS LEU SEQRES 19 A 276 LEU GLN LYS MET THR ASP LEU ARG GLN ILE VAL THR GLU SEQRES 20 A 276 HIS VAL GLN LEU LEU GLN VAL ILE LYS LYS THR GLU THR SEQRES 21 A 276 ASP MET SER LEU HIS PRO LEU LEU GLN GLU ILE TYR LYS SEQRES 22 A 276 ASP LEU TYR SEQRES 1 B 276 GLY ALA LEU ASN PRO GLU SER ALA ASP LEU ARG ALA LEU SEQRES 2 B 276 ALA LYS HIS LEU TYR ASP SER TYR ILE LYS SER PHE PRO SEQRES 3 B 276 LEU THR LYS ALA LYS ALA ARG ALA ILE LEU THR GLY LYS SEQRES 4 B 276 THR THR ASP LYS SER PRO PHE VAL ILE TYR ASP MET ASN SEQRES 5 B 276 SER LEU MET MET GLY GLU ASP LYS ILE LYS PHE LYS HIS SEQRES 6 B 276 ILE THR PRO LEU GLN GLU GLN SER LYS GLU VAL ALA ILE SEQRES 7 B 276 ARG ILE PHE GLN GLY CYS GLN PHE ARG SER VAL GLU ALA SEQRES 8 B 276 VAL GLN GLU ILE THR GLU TYR ALA LYS SER ILE PRO GLY SEQRES 9 B 276 PHE VAL ASN LEU ASP LEU ASN ASP GLN VAL THR LEU LEU SEQRES 10 B 276 LYS TYR GLY VAL HIS GLU ILE ILE TYR THR MET LEU ALA SEQRES 11 B 276 SER LEU MET ASN LYS ASP GLY VAL LEU ILE SER GLU GLY SEQRES 12 B 276 GLN GLY PHE MET THR ARG GLU PHE LEU LYS SER LEU ARG SEQRES 13 B 276 LYS PRO PHE GLY ASP PHE MET GLU PRO LYS PHE GLU PHE SEQRES 14 B 276 ALA VAL LYS PHE ASN ALA LEU GLU LEU ASP ASP SER ASP SEQRES 15 B 276 LEU ALA ILE PHE ILE ALA VAL ILE ILE LEU SER GLY ASP SEQRES 16 B 276 ARG PRO GLY LEU LEU ASN VAL LYS PRO ILE GLU ASP ILE SEQRES 17 B 276 GLN ASP ASN LEU LEU GLN ALA LEU GLU LEU GLN LEU LYS SEQRES 18 B 276 LEU ASN HIS PRO GLU SER SER GLN LEU PHE ALA LYS LEU SEQRES 19 B 276 LEU GLN LYS MET THR ASP LEU ARG GLN ILE VAL THR GLU SEQRES 20 B 276 HIS VAL GLN LEU LEU GLN VAL ILE LYS LYS THR GLU THR SEQRES 21 B 276 ASP MET SER LEU HIS PRO LEU LEU GLN GLU ILE TYR LYS SEQRES 22 B 276 ASP LEU TYR HET 9HO A1477 21 HET 9HO A1478 21 HET 9HO B1476 21 HETNAM 9HO (9S,10E,12Z)-9-HYDROXYOCTADECA-10,12-DIENOIC ACID FORMUL 3 9HO 3(C18 H32 O3) FORMUL 4 HOH *119(H2 O) HELIX 1 1 GLU A 207 PHE A 226 1 20 HELIX 2 2 THR A 229 GLY A 239 1 11 HELIX 3 3 ASP A 251 LYS A 261 1 11 HELIX 4 4 GLU A 276 SER A 302 1 27 HELIX 5 5 GLY A 305 LEU A 309 5 5 HELIX 6 6 ASP A 310 ALA A 331 1 22 HELIX 7 7 SER A 342 GLY A 344 5 3 HELIX 8 8 ARG A 350 SER A 355 1 6 HELIX 9 9 MET A 364 ALA A 376 1 13 HELIX 10 10 ASP A 380 LEU A 393 1 14 HELIX 11 11 ASN A 402 HIS A 425 1 24 HELIX 12 12 GLN A 430 GLU A 460 1 31 HELIX 13 13 HIS A 466 LYS A 474 1 9 HELIX 14 14 GLU B 207 PHE B 226 1 20 HELIX 15 15 THR B 229 GLY B 239 1 11 HELIX 16 16 ASP B 251 ILE B 262 1 12 HELIX 17 17 GLU B 276 SER B 302 1 27 HELIX 18 18 GLY B 305 LEU B 309 5 5 HELIX 19 19 ASP B 310 LEU B 333 1 24 HELIX 20 20 ARG B 350 LEU B 356 1 7 HELIX 21 21 PRO B 359 PHE B 363 5 5 HELIX 22 22 MET B 364 ALA B 376 1 13 HELIX 23 23 ASP B 380 LEU B 393 1 14 HELIX 24 24 ASN B 402 HIS B 425 1 24 HELIX 25 25 GLN B 430 LYS B 457 1 28 HELIX 26 26 HIS B 466 LYS B 474 1 9 SHEET 1 AA 4 PHE A 247 ILE A 249 0 SHEET 2 AA 4 GLY A 346 THR A 349 1 O PHE A 347 N ILE A 249 SHEET 3 AA 4 GLY A 338 ILE A 341 -1 O VAL A 339 N MET A 348 SHEET 4 AA 4 MET A 334 ASN A 335 -1 O ASN A 335 N GLY A 338 SHEET 1 BA 4 PHE B 247 ILE B 249 0 SHEET 2 BA 4 GLY B 346 THR B 349 1 O PHE B 347 N ILE B 249 SHEET 3 BA 4 GLY B 338 ILE B 341 -1 O VAL B 339 N MET B 348 SHEET 4 BA 4 MET B 334 ASN B 335 -1 O ASN B 335 N GLY B 338 CISPEP 1 LYS A 358 PRO A 359 0 0.05 CISPEP 2 LYS B 358 PRO B 359 0 0.18 SITE 1 AC1 12 ILE A 281 CYS A 285 ARG A 288 SER A 289 SITE 2 AC1 12 HIS A 323 LEU A 330 LEU A 353 PHE A 363 SITE 3 AC1 12 MET A 364 HIS A 449 TYR A 473 9HO A1478 SITE 1 AC2 13 PHE A 226 PRO A 227 LEU A 228 ARG A 288 SITE 2 AC2 13 GLU A 295 ILE A 326 MET A 329 LEU A 330 SITE 3 AC2 13 LEU A 333 SER A 342 GLU A 343 9HO A1477 SITE 4 AC2 13 HOH A2009 SITE 1 AC3 11 PHE B 282 CYS B 285 GLN B 286 ARG B 288 SITE 2 AC3 11 SER B 289 ILE B 326 TYR B 327 LEU B 333 SITE 3 AC3 11 PHE B 360 PHE B 363 MET B 364 CRYST1 93.182 61.674 118.941 90.00 103.02 90.00 C 1 2 1 8 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.010732 0.000000 0.002482 0.00000 SCALE2 0.000000 0.016214 0.000000 0.00000 SCALE3 0.000000 0.000000 0.008629 0.00000 MASTER 403 0 3 26 8 0 10 6 0 0 0 44 END